Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the relationship between PSF and PPARγ in colon cancer, we evaluated the effects of PSF expression in DLD-1 and HT-29 colon cancer cell lines, which express low and high levels of PPARγ, respectively PSF affected the ability of PPARγ to bind, and expression of PSF siRNA significantly suppressed the proliferation of colon cancer cells.
|
23516550 |
2013 |
Colon Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
High lutein intake [odds ratio (OR), 0.63; 95% confidence interval (95% CI), 0.44-0.89], low refined grain intake (OR, 0.70; 95% CI, 0.53-0.94), or a high prudent diet score (OR, 0.66; 95% CI, 0.49-0.89) and PA/AA PPARgamma genotype were associated with reduced colon cancer risk.
|
15894676 |
2005 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The activation of peroxisome proliferator-activated receptor gamma stimulated by thiazolidinedione is useful in the treatment of type II diabetes mellitus and may have value in preventing inflammatory bowel disease or colon cancer.
|
12946210 |
2003 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, PPARgamma protein levels are elevated, possibly through sequestration by activated beta-catenin in colon cancer cell lines.
|
15665104 |
2005 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This finding suggests a potentially important use for PPARgamma ligands as chemopreventative agents in colon cancer.
|
12370429 |
2002 |
Colon Carcinoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, EPA suppressed HT-29 cell growth and this effect was significantly reversed by the addition of GW, suggesting that in part the physiological actions of EPA are the result of PPARgamma activation.
|
18203887 |
2008 |
Colon Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Stratified meta-analysis indicated that PPAR-gamma 34 C>G was associated with colon cancer (OR = 0.8, 95% CI: 0.65-0.99, P = 0.04) in random-effect model, and the G allele decreased colon cancer risk.
|
20440859 |
2010 |
Colon Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The odd ratio for PPARgamma PA or AA genotype relative to the PP genotype for colon cancer was 0.9 (95% confidence interval, CI=0.8-1.0) and for rectal cancer was 1.2 (95% CI=1.0-1.5) adjusting for race, age, and sex.
|
15860437 |
2005 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We observed a marked synergism between peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and X-linked inhibitor of apoptosis (XIAP) down-regulation in colon cancer.
|
18704457 |
2009 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To better understand their role, we studied the expression levels of all PPAR-isoforms and transcriptional partners such as the retinoid X receptor alpha (RXRalpha) and PPARgamma-coactivator-1 (PGC-1) by means of real-time PCR in 17 patients with colon cancer.
|
14670614 |
2004 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, SOX9, β-catenin and PPARγ expression levels are deregulated in the CRC tissue, and in colon cancer cell lines ligand-dependent PPARγ activation unevenly influences SOX9 and β-catenin expression and subcellular localization, suggesting a variable mechanistic role in colon carcinogenesis.
|
23583560 |
2013 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPARgamma.
|
9734398 |
1998 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Comparison of the transcriptome data of metastasis-competent CTC-MCC-41 cells and of HT-29 cells (derived from a primary colon cancer) highlights the differential expression of genes that regulate energy metabolism [peroxisome proliferator-activated receptor γ coactivator 1A (<i>PPARGC1A</i>), peroxisome proliferator-activated receptor γ coactivator 1B (<i>PPARGC1B</i>), fatty acid binding protein 1 (<i>FABP1</i>), aldehyde dehydrogenase 3 family member A1 (<i>ALDH3A1</i>)], DNA repair [BRCA1 interacting protein C-terminal helicase 1 (<i>BRIP1</i>), Fanconi anemia complementation group B (<i>FANCB</i>), Fanconi anemia complementation group M (<i>FANCM</i>)], and stemness [glutaminase 2 (<i>GLS2</i>), cystathionine-beta-synthase (<i>CBS</i>), and cystathionine gamma-lyase (<i>CTH</i>)].
|
28007957 |
2017 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone.
|
14634802 |
2004 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To elucidate cdk5's role in PPARgamma ligand-induced antiproliferation of colon cancer cells, HT-29 cells were treated with ciglitazone.
|
16327995 |
2006 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Based on our findings, p38 MAPK and transcription factor PPARgamma can be considered as molecular targets of resveratrol in the regulation of cell proliferation and SSAT activity, respectively, in a cell culture model of colon cancer.
|
16849586 |
2006 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We can therefore exclude this alteration as a mechanism of resistance to PPAR(gamma) ligands in patients with colon cancer.
|
15911106 |
2005 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that PPARgamma plays a role as a physiological regulator of colonic epithelial cell turnover and consequently predisposition to the development of colon cancer in early stage.
|
18391483 |
2008 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The molecules and signals that act to eradicate or initiate the apoptosis cascade in cancer cells, are elucidated, and these include caspases, Fas, Bax, Bid, APC, antisense hTERT, PUMA, 15-LOX-1, ceramide, butyrate, tributyrin and PPARgamma, whereas the molecules which promote colon cancer cell survival are p53 mutants, Bcl-2, Neu3 and COX-2.
|
15255176 |
2004 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This suggests that PPARγ expression may be an important factor for cell growth regulation in colon cancer.
|
22771328 |
2012 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Transient exposure to CDDP and induction of the CDDP resistance decreased expression of peroxisome proliferator-activated receptor-γ (PPARγ) in MKN45 and colon cancer LoVo cells.
|
27417252 |
2016 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated if the rexinoid 6-OH-11-O-hydroxyphenantrene (IIF) potentiates the antitumoral properties of PPARgamma ligands as ciglitazone and pioglitazone, on two colon cancer cell lines: HCA-7 and HCT-116.
|
20510503 |
2010 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
1,1-Bis(3'indolyl)-1-(p-substitutedphenyl)methanes containing p-trifluoromethyl (DIM-C-pPhCF)), p-t-butyl (DIM-C-pPhtBu), and p-phenyl (DIM-C-pPhC6H5) groups induce peroxisome proliferator-activated receptor gamma (PPARgamma)-mediated transactivation in HT-29, HCT-15, RKO, and SW480 colon cancer cell lines.
|
15342379 |
2004 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, dihydroartemisinin inhibits colon cancer growth by inducing apoptosis and increasing the expression of PPARγ.
|
29472793 |
2018 |